Introduction &
Biliary atresia (BA) is a neonatal disorder characterized by progressive cholangiopathy aff ecting both extrahepatic and intrahepatic bile ducts. It may lead to obliteration or discontinuity of the biliary tract at any point between the porta hepatis and the duodenum. When untreated, BA patients develop severe liver injury, biliary cirrhosis, and ultimately die by the age of two years [2] . The standard surgical therapy of BA is early Kasai portoenterostomy. Despite early diagnosis and successful Kasai operation, more than half of BA patients still develop hepatic fi brosis, portal hypertension, and end-stage liver disease [6] . Alternatively, liver transplantation is an eff ective treatment modality if the Kasai portoenterostomy fails and serious complications occur such as recurrent cholangitis, persistent jaundice, cirrhosis, progressive ascites, and bleeding esophageal varices [7] . Although several etiologies of BA have been postulated, including neonatal viral The purpose of this study was to investigate the association between cyclooxygenase-2 (COX-2) expression and clinical outcome in biliary atresia (BA) patients. Methods: Six months after surgery, twentyeight BA patients were divided into three groups according to their liver function tests: group A with satisfactory liver function (n = 11), group B with moderate liver dysfunction (n = 8), and group C with severe liver dysfunction (n = 9). COX-2 expression was determined by immunohistochemistry. Choledochal cysts (n = 5) and normal liver samples (n = 4) served as controls. Results: Our data have shown that the intrahepatic biliary epithelium in BA specimens expressed COX-2. The mean immunoreactive score of COX-2 in BA patients was signifi cantly higher than that in choledochal cyst and normal liver (4.0 ± 0.6, 0.9 ± 0.3, and 0.7 ± 0.3, respectively, p < 0.002). Strong expression of COX-2 was observed in BA patients with severe liver dysfunction. Subgroup analysis showed that the mean COX-2 immunoreactive scores of patients in group A, B, and C were 2.1 ± 0.6, 3.6 ± 1.1, and 5.9 ± 0.9, respectively. The COX-2 immunoreactive score in BA patients with severe liver dysfunction was higher than in patients with satisfactory liver function (p < 0.005).
Conclusion:
Increased COX-2 expression of biliary epithelial cells at the time of Kasai operation was associated with an adverse therapeutic outcome in BA, suggesting that COX-2 could play a plausible role in the liver pathology of BA.
overexpression of COX-2 in the livers of patients with chronic viral hepatitis [4] , cirrhosis [18] , and hepatocellular carcinoma [19, 15] . In bile duct ligation animal models of liver injury, COX-2 expression was signifi cantly upregulated with COX-2 mRNA and protein localized to proliferating bile duct epithelial cells [14, 24] . However, the possibility that COX-2 could contribute to the pathogenesis and clinical outcome of BA has not been investigated.
To the best of our knowledge, there have been no published studies on COX-2 expression in liver specimens of patients with BA. We postulated that increased COX-2 expression would be associated with severity of the liver injury in BA and the expression pattern of COX-2 would be primarily in biliary epithelial cells in BA. Therefore, the aims of this study were to investigate the pattern of COX-2 expression in liver specimens from children with BA and to determine the potential association between the COX-2 expression and clinical outcome of BA patients. In the present study, COX-2 expression was analyzed in the intrahepatic biliary epithelium in BA patients using an immunohistochemical technique.
Patients and Methods &
This study was approved by the Ethics Committee on Human Research of the Faculty of Medicine, Chulalongkorn University. All parents of children with BA and controls were informed of the study ' s purpose. Written informed consent was obtained for all patients who participated in this study.
Patients
Liver samples were obtained from 28 BA patients (11 boys and 17 girls; age range 1 -5 months; mean 86 days) while undergoing Kasai portoenterostomy with a Roux-en-Y (original Kasai) operation at the Department of Surgery, Chulalongkorn University, between 2001 and 2006. Specimens from choledochal cysts (n = 5) from patients with ages ranging from 1 month to 10 months (mean 4.5 months) and normal liver (n = 4) specimens from patients with an age range from 10 months to 98 months (mean 34.4 months) served as controls. Liver specimens were routinely evaluated histologically with hematoxylin and eosin staining. Formalin-fi xed and paraffi n-embedded specimens for immunostaining were obtained from our pathology archives. The duration of follow-up after the Kasai operation ranged from 6 months to 72 months (mean 34 months). Serum samples were collected from each patient at the time of their follow-up and stored at − 80 ° C. Liver function tests, including total bilirubin (TB), direct bilirubin (DB), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were performed by routine laboratory methods using an automated machine (Hitachi 912, Roche Diagnostics, Basel, Switzerland). In order to associate COX-2 expression with clinical outcome at 6 months post-Kasai in BA children, the children were categorized into 3 groups according to their levels of serum total bilirubin and liver enzymes. Group A consisted of 11 patients with satisfactory liver function (TB < 2 mg / dl, AST < 40 IU / l, ALT < 40 IU / l). Group B consisted of 8 patients with moderate liver dysfunction (TB < 2 mg / dl, AST ≥ 40 IU / l, ALT ≥ 40 IU / l). Group C consisted of 9 patients with severe liver dysfunction (TB ≥ 2 mg / dl, AST ≥ 40 IU / l, ALT ≥ 40 IU / l), who subsequently underwent liver transplantation.
Immunohistochemistry of the COX-2 stained liver specimens
Tissue specimens were fi xed in 10 % buff ered formalin and embedded in paraffi n. Serial sections (5 μ m) of paraffi n-embedded tissue were cut and processed for COX-2 staining. Sections were deparaffi nized and rehydrated in Tris-buff ered saline. Endogenous peroxidase activity was blocked with 0.3 % H 2 O 2 for 10 min. For antigen retrieval, tissue sections were microwave heated in 10 mmol / L citrate buff er for 5 min. Nonspecifi c binding was blocked for 10 min with 5 % goat serum (DAKO, Glostrup, Denmark), followed by incubation with antibody to COX-2 (1:100; Diagnostic Biosystems, Pleasanton, CA, USA) in Tris-buffered saline containing 2 % rabbit serum and 1 % bovine serum albumin for 2 hours. Tissues were incubated with the same buff er without the antibody to serve as negative controls. Sections were subsequently stained with biotinylated goat antirabbit immunoglobulins (1:400; DAKO) and streptavidin / horseradish peroxidase complex (1:400; DAKO) and incubated at room temperature for 45 min. Reaction products were visualized using diaminobenzidine (Sigma, St. Louis, MO, USA) as the chromogen. The sections were subsequently counterstained with Mayer ' s hematoxylin and mounted onto microscope slides using a permanent medium.
COX-2 immunohistochemistry staining score
All stained specimens were assessed blindly without knowledge of the patient subgroups, clinical and histology parameters. 
Statistical analysis
Comparisons of clinicopathological parameters between groups were performed using Student ' s t -test and Mann -Whitney Utest. Statistical signifi cance was considered achieved if the pvalue was less than 0.05. Data are expressed as mean ± SEM. All analyses were conducted using the Statistical Package for Social Sciences (SPSS) for Windows (version 16) computer program.
Results & COX-2 expression was barely detectable as a faint cytoplasm staining in the control liver specimens. However, the expression of COX-2 in the BA specimens was upregulated in infl ammatory cells, vascular endothelial cells, the epithelial cells lining the intrahepatic bile ducts, and cells of the surrounding connective tissue ( • ▶ Fig. 1 ). COX-2 was expressed in the cytoplasm of the positive cells. More intense expression was observed in BA subjects compared with controls for COX-2 expression on intrahepatic bile ducts. As illustrated in • ▶ Table 1 , the mean immunoreactive score of COX-2 in the BA patients was signifiDownloaded by: Chulalongkorn University. Copyrighted material.
cantly higher than in choledochal cysts and normal liver (4.0 ± 0.6, 0.9 ± 0.3, and 0.7 ± 0.3, respectively; p < 0.002). The COX-2 immunoreactive scores of the distinctive groups of BA patients are shown in • ▶ Table 2 . Liver biopsy specimens from group C subjects revealed that COX-2 was expressed strongly on biliary epithelial cells and some infl ammatory cells but not on the hepatocytes. In contrast, liver biopsy specimens from group A subjects showed slight COX-2 reactivity on the epithelial lining of intrahepatic bile ducts ( • ▶ Fig. 1 ). As demonstrated in • ▶ Table 2 , the total COX-2 immunoreactive scores of BA patients in groups A, B, and C were 2.1 ± 0.6, 3.6 ± 1.1, and 5.9 ± 0.9, respectively. The average immunoreactive score for COX-2 expression was signifi cantly increased in group C subjects compared with that in group A subjects (p < 0.005, • ▶ Fig. 2 ). However, there was no signifi cant diff erence in the COX-2 immunoreactive score of group B compared with other groups.
Discussion & Prostaglandins (PG) are essential mediators of infl ammation, with their synthesis initiated by the release of arachidonic acid from cell membranes. COX stimulates the conversion of arachidonic acid to PGH 2 and is a rate-limiting enzyme in the biosynthesis of prostanoid [20, 10] . COX-1 is generally present in almost all normal tissues and performs housekeeping functions such as gastric cytoprotective action and homeostasis. COX-2 accounts for the increased production of PG in many cell types induced by various factors, such as mitogens, hormones, growth factors, and cytokines. COX-2 is also actively involved in infl ammation, fi brogenesis, and wound healing [16] . Previous studies have shown that COX-2 is not expressed in normal biliary epithelium whereas COX-2 overexpression is correlated with the degree of hepatic infl ammation and the development of hepatic fi brosis [17] . However, the impact of COX-2 expression on the clinical course of BA has not been characterized. Biliary atresia (BA) remains one of the most common causes of pathologic jaundice in neonates and presents with the triad of jaundice, acholic stools and hepatosplenomegaly. The etiology and pathogenesis of BA largely remain unknown, and therapeutic options are unsatisfactory. Irrespective of the initiating disorder, all children with BA share a unique progressive infl ammatory and fi brotic obstruction of the biliary system [2, 6, 1] . Macroscopically, the livers of children with BA are fi rm with dark green discoloration and nodular degeneration of cirrhosis. During the early stages, microscopic fi ndings of hepatic histology typically show bile pigment in hepatocytes and canaliculi, portal tract widening, and bile duct proliferation [7] . Disease progression leads to liver fi brosis and cirrhosis with concomitant portal hypertension and hepatic failure. Although there have been several studies focusing on the role of growth factors in BA patients including serum levels of growth factors [11, 21] and cytokines [3, 12, 22] , the determination of COX-2 expression in biliary atresia patients has received little attention.
To the best of our knowledge, this is the fi rst study that demonstrates the relationship between COX-2 expression in liver specimens and the clinical outcome of BA. The current investigation has demonstrated that COX-2 expression in the intrahepatic biliary epithelium of BA patients is signifi cantly higher than that of controls. Moreover, we have shown that COX-2 expression is associated with serum levels of total bilirubin, aspartate aminotransferase, and alanine aminotransferase, although we cannot rule out that these associations might be attributable to advanced hepatic fi brosis in the BA children. COX-2 overexpression has been documented in a number of liver diseases including chronic hepatitis [4] , liver cirrhosis [5, 18] , and hepatocellular carcinoma [9, 15, 19] . In agreement with our fi ndings, Pazirandeh et al. have demonstrated that COX-2 expression is significantly increased in patients with liver cirrhosis and is associated with liver infl ammation and fi brosis stage [19] . Cheng et al. have also shown upregulation of hepatic COX-2 expression along with progression of liver fi brosis in chronic liver diseases [5] . These fi ndings suggest that upregulated COX-2 expression is associated with hepatic damage and hence, refl ects hepatic fi brosis. Our immunohistochemistry data demonstrate positive cytoplasmic COX-2 expression in infl ammatory cells and biliary epithelial cells of bile ductules. Subsequent analysis has shown that the total COX-2 immunoreactive score is signifi cantly higher in BA patients with severe liver dysfunction compared to those with satisfactory liver function. COX-2 overexpression in the bile ductule epithelium of liver specimens at the initial operation might be a poor prognostic factor in BA and appears to be associated with the severity of liver injury, suggesting its signifi cant involvement in the pathophysiology of BA. Although these fi ndings do not prove a direct cause and eff ect relationship, they provide further evidence that liver infl ammation and hepatic dysfunction could be COX-2 dependent processes. More studies using animal models of liver injury such as bile duct ligation, and transgenic mice with liver-specifi c overexpression of COX-2 will be required to elucidate the role of COX-2 in hepatic injury and fi brosis of BA. biliary atresia (n = 28) 4.0 ± 0.6 * choledochal cyst (n = 5) 0.9 ± 0.3 normal liver (n = 4) 0.7 ± 0.3
In this study, we are aware of some limitations. Firstly, most data were gathered retrospectively, making its quality variable. Secondly, the sample size of BA patients was not large enough to draw strong conclusions. The small number of patients makes it diffi cult to show statistical diff erences between patient groups even though the data appear to show diff erences. However, with the scarcity of biliary atresia, the results of a study based on liver specimens of 28 BA patients cannot be disregarded. Lastly, upregulation of hepatic COX-2 expression might be just the nonspecifi c fi ndings of cholestasis. Additional investigations of non-BA children with cholestasis will clarify this point.
To summarize, the present study has demonstrated the overexpression of COX-2 in the liver specimens of BA patients compared to those of controls. The COX-2 immunoreactive score in BA patients with poor outcomes was signifi cantly higher than that of patients with good outcomes and controls. Our study has shown that increased COX-2 expression in intrahepatic biliary epithelium at the time of Kasai operation was associated with an adverse therapeutic outcome and could play a possible role in the liver pathology of BA. Clinical application of COX-2 modulation may contribute to the development of therapeutic agents for BA patients. Further studies examining the impact of selective COX-2 inhibitors on infl ammation and progression of liver fi brosis in BA are required. The use of selective COX-2 inhibitors in BA patients may help attenuate hepatic infl ammation and potentially help prevent or provide treatment for hepatic fi brosis. Data are expressed as mean and SEM. The mean COX-2 immunoreactive score of group C was signifi cantly increased when compared with that of group A (p < 0.005). Group A, satisfactory liver function; group B, moderate liver dysfunction; group C, severe liver dysfunction. Table 2 Variables for total scores of COX-2 immunostaining of liver specimens in BA patients. Group A, satisfactory liver function; group B, moderate liver dysfunction; group C, severe liver dysfunction. 
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